All In Biotech

Drug Trial Radar · NCT02257918

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

A Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of a Single Dose of Oral AZD0914 Compared to Intramuscular Ceftriaxone in the Treatment of Male and Female Subjects With Uncomplicated Gonorrhea

Last checked: Nov 20, 2026Latest source record: Mar 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Nov 25, 2014

Primary completion

Dec 30, 2015

Study completion Dec 30, 2015

Sponsor

Sponsor type
NIH
First posted
Oct 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria. The study is designed to assess the safety and efficacy of an antimicrobial investigational product, AZD0914 manufactured by AstraZeneca, administered to adults to treat uncomplicated urogenital gonorrhea compared to treatment with ceftriaxone. Subjects will be randomly assigned 70:70:40 to receive a single, oral dose of 2000 mg of AZD0914, 3000 mg of AZD0914, or intramuscular dose of 500 mg of ceftriaxone. The drug name is also known as ETX0914.

Conditions

  • Gonorrhoea

Interventions

  • AZD0914Drug

    AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.

  • CeftriaxoneDrug

    Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study ArmTime frame: Day 6
  2. Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Considered Product-related.Time frame: Day 1 through Day 31

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Jefferson County Department of Health - STD Clinic

    Birmingham, Alabama

  • Indiana University - Bell Flower Clinic

    Indianapolis, Indiana

  • CrescentCare Health and Wellness Center

    New Orleans, Louisiana

  • Durham County Health Department

    Durham, North Carolina

  • Public Health STD Clinic

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.